Composition and methods for identification of novel aav variants for differentiated gene delivery to cardiomyoctes and / or skeletal myofibers

Abstract

The present invention relates to the provision of recombinant adeno-associated virus (rAAV) -based delivery vectors comprising short peptide inserts of at least 5 amino acid length, which show enhanced transduction efficiency in one or more muscle cells, particularly in cardiomyocytes and / or skeletal muscle cells. The rAAV vectors of the present disclosure are suitable for use in the treatment and / or prophylaxis of a cardiac-related and / or muscle-related disease or disorder and / or for use in gene therapy. Also provided are methods of treating cardiac-related and / or muscle-related diseases or disorders.

Images